1. The effects of plasma viscosity in thromboembolic events among patients with essential thrombocytosis: A case-control study
- Author
-
Afra Alkan, Tekin Guney, Ferda Can, Imdat Dilek, and Sema Akıncı
- Subjects
medicine.medical_specialty ,Physiology ,medicine.drug_class ,Gastroenterology ,Polycythemia vera ,Thromboembolism ,Physiology (medical) ,Internal medicine ,Humans ,Medicine ,Platelet ,Plasma viscosity ,Thrombocytosis ,Viscosity ,business.industry ,Essential thrombocythemia ,Anticoagulant ,Case-control study ,Hematology ,medicine.disease ,Thrombosis ,Case-Control Studies ,Cardiology and Cardiovascular Medicine ,business ,Thrombocythemia, Essential - Abstract
INTRODUCTION: Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia where in the thrombocytes are increased with abnormal function. Thrombotic events are seen frequently and represent the main cause of morbidity and mortality in patients with MPNs, mainly polycythemia vera and ET. This study has aimed to research the effects of clonally increased thrombocytes on plasma viscosity (PV) levels among patients with ET and the relationship between PV and thromboembolism history, according to the hypotheses about the effects of PV in thromboembolic events among patients with ET. METHODS: A total of 55 patients were enrolled in the study group, 18 of who had been newly diagnosed with ET according to 2016 World Health Organization criteria and had not previously been treated. 37 of them had already been diagnosed with ET and had been treated. There were 47 healthy volunteers in the control group. 5 cc blood samples were taken from the patients into tubes including an anticoagulant to measure their PV levels. RESULTS: PV of the control group was found to be lower than in the study group and both each patient groups (p
- Published
- 2022